2 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Morten Ladekarl: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer Gemcitabine, Nab paclitaxel - Pancreas Cancer, Non-Resectable Pancreas Carcinoma | Phase 2 | Recruiting | Morten Ladekarl | 98 | 2023-06-12 | 2025-01-29 |
| Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment Solid Tumor, Unspecified, Adult, Haematological Malignancy | Recruiting | Morten Ladekarl | 3000 | 2020-07-01 | 2024-01-31 |
Hematologic Neoplasms (1) · Pancreatic Neoplasms (1)
Albumin-Bound Paclitaxel (1) · Gemcitabine (1) · Taxes (1)
Denmark (2)